Skip to main content

Table 3 A breakdown of all-cause total treatment costs according to risk factors

From: Economic burden of community-acquired pneumonia among elderly patients: a Japanese perspective

 

Total episodes

Proportion of CAP episodes (%)

Total costs

Proportion of total costs (%)

Risk factors

n

Outpatient episodes

GW episodes

ICU episodes

$

%

Outpatient episodes

GW episodes

ICU episodes

Total

34,764

41.6%

57.9%

0.5%

136,575,963

100.0%

5.6%

92.2%

2.2%

Sex

 Male

21,167

41.8%

57.6%

0.6%

83,776,408

61.3%

5.8%

91.7%

2.5%

 Female

13,597

41.2%

58.5%

0.4%

52,799,556

38.7%

5.4%

93.0%

1.6%

Age group

 65–74 years

10,286

56.3%

43.3%

0.5%

31,437,785

23.0%

10.8%

85.5%

3.7%

 75–84 years

13,577

41.3%

58.1%

0.6%

54,022,674

39.6%

5.6%

92.4%

2.0%

  ≥ 85 years

10,901

28.0%

71.6%

0.4%

51,115,505

37.4%

2.5%

96.1%

1.3%

Comorbidities

 Diabetes mellitus

3982

49.0%

50.3%

0.8%

14,534,072

10.6%

8.9%

88.2%

3.0%

 COPD

4935

49.2%

50.3%

0.6%

16,749,527

12.3%

8.2%

89.6%

2.3%

 Liver function failure

5793

52.1%

47.4%

0.5%

19,154,382

14.0%

9.2%

88.5%

2.2%

 Dementia

238

43.3%

55.9%

0.8%

936,780

0.7%

5.5%

90.0%

4.5%

 Dialysis

675

43.4%

55.6%

1.0%

3,592,463

2.6%

9.1%

83.9%

7.0%

 Rheumatism

1109

55.9%

43.7%

0.4%

3,533,324

2.6%

11.4%

84.9%

3.7%

 Cancer

3606

63.3%

36.4%

0.3%

9,999,506

7.3%

18.6%

80.0%

1.4%

Prescriptions during previous 6 months

 Oral antibiotics

3830

58.6%

40.8%

0.6%

11,646,586

8.5%

13.7%

82.8%

3.5%

 Inhaled steroids

2434

52.5%

46.6%

0.8%

7,329,868

5.4%

9.7%

86.9%

3.4%

 ACE-I

1091

46.3%

53.0%

0.7%

4,087,905

3.0%

7.0%

90.8%

2.2%

 Statins

3261

51.5%

47.7%

0.9%

10,744,840

7.9%

9.0%

87.2%

3.9%

  1. CAP community-acquired pneumonia, GW general ward, ICU intensive care unit, COPD chronic obstructive pulmonary disease, ACE-I angiotensin-converting enzyme inhibitors